KEN NGUYEN: Open Payments
NPI 1205193828 · TEMPLE CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$30,256 in 170 payments from 13 companies in 2025. Trend: 2023 $15,077 · 2024 $33,269 · 2025 $30,256
Speaker / faculty: $25,630Food & beverage: $4,542Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 53 | $12,607 |
| Ardelyx, Inc. | 19 | $7,896 |
| Phathom Pharmaceuticals, Inc. | 17 | $7,439 |
| Boston Scientific Corporation | 12 | $669 |
| Madrigal Pharmaceuticals | 16 | $547 |
| Janssen Biotech, Inc. | 20 | $353 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $279 |
| Gilead Sciences, Inc. | 8 | $165 |
| PFIZER INC. | 6 | $120 |
| QOL Medical, LLC | 3 | $64 |
Products named: IBSRELA, VOQUEZNA, LINZESS, CREON, REZDIFFRA, TREMFYA, RINVOQ, XIFAXAN.
Industry payments across CA — which companies pay providers there.
